TY  - JOUR
AU  - Rühle, Alexander
AU  - Grosu, Anca-L
AU  - Wiedenmann, Nicole
AU  - Stoian, Raluca
AU  - Haehl, Erik
AU  - Zamboglou, Constantinos
AU  - Baltas, Dimos
AU  - Werner, Martin
AU  - Kayser, Gian
AU  - Nicolay, Nils
TI  - Immunohistochemistry-based hypoxia-immune prognostic classifier for head-and-neck cancer patients undergoing chemoradiation - Post-hoc analysis from a prospective imaging trial.
JO  - Radiotherapy and oncology
VL  - 159
SN  - 0167-8140
CY  - Amsterdam [u.a.]
PB  - Elsevier Science
M1  - DKFZ-2021-00704
SP  - 75-81
PY  - 2021
N1  - 2021 Mar 19;159:75-81 / #EA:E055#LA:E055#
AB  - As both tumor hypoxia and an immunosuppressing tumor microenvironment hamper the anti-tumor activity of radiotherapy in head-and-neck squamous cell carcinoma (HNSCC), we aimed to develop an immunohistochemistry-based hypoxia-immune classifier.39 patients receiving definitive chemoradiation for HNSCC within a prospective trial were included in this analysis. Baseline tumor samples were analyzed for the hypoxia marker carbonic anhydrase IX (CAIX) and tumor-infiltrating lymphocytes (TILs) and were correlated with [18F]-misonidazole ([18F]FMISO) PET measurements. The impact of the biomarkers on the locoregional control (LRC) was examined using Cox analyses and concordance index statistics.Low CAIX (HR=0.352, 95
KW  - Carbonic anhydrase IX (Other)
KW  - FMISO PET (Other)
KW  - Head-and-neck squamous cell carcinoma (Other)
KW  - Hypoxia (Other)
KW  - Radiotherapy biomarker (Other)
KW  - Tumor-infiltrating lymphocytes (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:33753155
DO  - DOI:10.1016/j.radonc.2021.03.014
UR  - https://inrepo02.dkfz.de/record/168136
ER  -